Novartis Presents Five-Year Data for Cosentyx in Non-Radiographic Axial Spondyloarthritis

Novartis today presented five-year follow-up data from the Phase 3 PREVENT trial evaluating Cosentyx (secukinumab) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). The data showed that Cosentyx maintained significant improvements in disease activity, physical function, and quality of life over five years of treatment.